Ensartinib dihydrochloride

Overview

Ensartinib dihydrochloride (X-396 dihydrochloride) is a BBB-permeable and dual ALK / MET inhibitor with IC 50 s of <0.4 nM and 0.74 nM, respectively.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Neurological Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > c-Met/HGFR

Product Information

• Catalog No.: HY-103714A
• CAS No.: 2137030-98-7
• Molecular Formula: C26H29Cl4FN6O3
• Molecular Weight: 634.36
• Purity: 99.73%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.08 mg/mL (3.28 mM); Clear solution
• Availability: In-stock

Source

Original product source